Results 21 to 30 of about 338,185 (301)
Repurposing Interleukin-6 Inhibitors to Combat COVID-19. [PDF]
, 2020 Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications across the world. One of the most frequent causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus disease 2019 (COVID-19), which is associated
Kato, Shumei, Kurzrock, Razelle
core +1 more source
Molecules, 2022 In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the province of Wuhan, China.
Liliana Rodrigues +4 more
doaj +1 more source
Future Internet, 2021 The current global crisis caused by COVID-19 almost halted normal life in most parts of the world. Due to the long development cycle for new drugs, drug repositioning becomes an effective method of screening drugs for COVID-19. To find suitable drugs for
Mingxuan Che +4 more
doaj +1 more source
Clinical trials on drug repositioning for COVID-19 treatment [PDF]
Revista Panamericana de Salud Pública, 2020 The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genusBetacoronavirus, that is distributed in birds, humans, and other mammals.
Sandro G. Viveiros Rosa +1 more
openaire +3 more sources
Pentoxifylline: An Immunomodulatory Drug for the Treatment of COVID-19
Journal of Pure and Applied Microbiology, 2020 Rapidly spreading outbreak of the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is causing serious health concerns worldwide.
Hiren A. Dhameliya +4 more
doaj +1 more source
Secondary Publication: COVID-19 Pandemic: Drug Development and Treatment
Tokyo Women's Medical University Journal, 2021 Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019. It has been rapidly spreading worldwide ever since.
Fujiko Tsukahara, Yoshiro Maru
doaj +1 more source
A brief overview of current drug repurposing approaches for COVID-19 management [PDF]
, 2020 This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19).
Rodrigues, Pedro da Fonseca Soares +1 more
core +2 more sources
Treatments for COVID-19: emerging drugs against the coronavirus.
Acta bio-medica : Atenei Parmensis, 2020 The Coronavirus disease 19 (COVID-19) outbreak has been recognized as a global threat to public health. It is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and no effective therapies currently exist against this novel viral agent.
Potì, Francesco +4 more
openaire +5 more sources
Medicine in Drug Discovery, 2020 The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden.
Jiayu Liao, George Way, Vipul Madahar
doaj +1 more source
ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential
Pharmaceuticals, 2021 On 11 March 2020, the World Health Organization (WHO) classified the Coronavirus Disease 2019 (COVID-19) as a global pandemic, which tested healthcare systems, administrations, and treatment ingenuity across the world.
Subrata Deb +3 more
doaj +1 more source